INS and type 1 diabetes mellitus: The EASE (Empagliflozin as Adjunctive to inSulin thErapy)-1 and -2 programs investigated EMPA in T1D subjects and showed a clear beneficial effect on HbA1c, body weight, blood pressure, glucose variability, and total daily insulin use with minimal adverse events [39,40].